Drug-mediated inhibition of MET activation

Stable Identifier
R-HSA-9734091
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

MET receptor tyrosine kinase (RTK) is a proto-oncogene that is frequently aberrantly activated in cancer through gene amplification and/or activating mutations that result in hypersensitivity to HGF stimulation or HGF-independent activation. Oncogenic MET activation can occur as a primary mechanism of malignant transformation or be selected secondarily, as a mechanism of resistance to therapeutics that target related RTKs, such as EGFR. MET targeted anti-cancer therapeutics, either recombinant monoclonal antibodies (MAbs) or small tyrosine kinase inhibitors (TKIs), have shown promise as a first-line agents for the treatment of solid tumors with primary MET activation or as second-line agents for the treatment of solid tumors with acquired MET-mediated resistance to other RTK-targeted therapies (reviewed in Comoglio et al. 2018).

Literature References
PubMed ID Title Journal Year
29674709 Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy

Comoglio, PM, Trusolino, L, Boccaccio, C

Nat Rev Cancer 2018
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!